🏛️ Verified NIH Record • Updated 2026-02-26
QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations (NCT06715124)
A Phase 1 Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations
🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Quanta Therapeutics
🩺 Plain-English Summary (8th-Grade Level)
Phase 1 study to determine the safety, tolerability, and anti-tumor activity of QTX3544 as a single agent or in combination with cetuximab.
Who can join: Review the eligibility criteria below.
Location: Sarah Cannon Research Institute — Denver, Colorado
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (10 Sites)
- Sarah Cannon Research Institute — Denver, Colorado
- Yale Cancer Center — New Haven, Connecticut
- Florida Cancer Specialists & Research Institute — Sarasota, Florida
- South Texas Accelerated Research Therapeutics, LLC Midwest — Grand Rapids, Michigan
- Duke Cancer Center — Durham, North Carolina
- Sarah Cannon Research Institute — Nashville, Tennessee
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- South Texas Accelerated Research Therapeutics, LLC San Antonio — San Antonio, Texas
- Huntsman Cancer Institute, University of Utah — Salt Lake City, Utah
- South Texas Accelerated Research Therapeutics Mountain Region, LLC — West Valley City, Utah
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Solid Tumors
- A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma — Scottsdale, Arizona
- A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer — Orange, California
- A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors — Denver, Colorado
- A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer — Scottsdale, Arizona
- A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations — Los Angeles, California
Explore by condition: All Advanced Solid Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.